Literature DB >> 9794154

Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation.

D Lucas1, C Farez, L G Bardou, J Vaisse, J R Attali, P Valensi.   

Abstract

Cytochrome P450 2E1 (CYP2E1) is a phase I detoxification enzyme, which is induced by chronic alcohol consumption. It is involved in the activation of numerous carcinogens and in the production of free radicals. As it has previously been shown to be induced in diabetic and obese rats, the aim of this study was to investigate its induction level in poorly-controlled diabetics and in obese patients (Body Mass Index > 30 kg/m2). CYP2E1 activity was determined in 35 diabetic and 17 obese patients by using the in vivo chlorzoxazone hydroxylation test. Even though the glucidic parameters were highly disturbed (mean fasting glycemia > 7.9 mmol/L, post prandial glycemia > 12.2 mmol/L and fructosamine > 326 mumol/L), CYP2E1 activity was not enhanced either in insulin-dependent diabetics (IDDs, n = 7) nor in non-obese non-insulin-dependent diabetics (NIDDs, n = 15) when compared to controls (n = 42) (0.21 +/- 0.03, 0.33 +/- 0.03 and 0.30 +/- 0.02, respectively, mean +/- SEM). However, this activity was lower in IDDs when compared to NIDDs (P < 0.05). In obese patients, with (n = 13) or without (n = 17) NIDD mellitus, CYP2E1 activity was increased by a mean of 40% when compared to controls. In addition, positive correlations were found in all subjects (controls or patients, n = 74) between CYP2E1 activity and serum cholesterol (r = 0.42, P < 0.0001), triglycerides (r = 0.44, P < 0.0001) and BMI (r = 0.36, P < 0.001). Accordingly, subjects with cholesterol and/or triglyceride serum levels above 6.4 and 1.8 mmol/L, respectively, displayed a mean increase of 40% of their CYP2E1 activity vs subjects within the above values. It is believed that individuals with increased CYP2E1 activity are more susceptible to the adverse effects of CYP2E1-mediated activation of toxins and carcinogens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9794154     DOI: 10.1111/j.1472-8206.1998.tb00985.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  23 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

2.  Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes.

Authors:  Dan Xu; Feng Li; Mian Zhang; Ji Zhang; Can Liu; Meng-yue Hu; Ze-yu Zhong; Ling-ling Jia; Da-wei Wang; Jie Wu; Li Liu; Xiao-dong Liu
Journal:  Acta Pharmacol Sin       Date:  2014-08-25       Impact factor: 6.150

3.  Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses.

Authors:  Nicolas Hohmann; Antje Blank; Jürgen Burhenne; Yosuke Suzuki; Gerd Mikus; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2019-08-09       Impact factor: 4.335

Review 4.  Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol).

Authors:  Lingtak-Neander Chan; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

5.  Cytochrome P450 (CYP) epoxygenases as potential targets in the management of impaired diabetic wound healing.

Authors:  Huichen Zhao; Jicui Chen; Jiachao Chai; Yuchao Zhang; Cong Yu; Zhe Pan; Peng Gao; Chen Zong; Qingbo Guan; Yuqin Fu; Yuantao Liu
Journal:  Lab Invest       Date:  2017-03-20       Impact factor: 5.662

Review 6.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

Review 7.  Drug disposition in pathophysiological conditions.

Authors:  Adarsh Gandhi; Bhagavatula Moorthy; Romi Ghose
Journal:  Curr Drug Metab       Date:  2012-11       Impact factor: 3.731

8.  Human cytochrome P450 2E1 structures with fatty acid analogs reveal a previously unobserved binding mode.

Authors:  Patrick R Porubsky; Kevin P Battaile; Emily E Scott
Journal:  J Biol Chem       Date:  2010-05-12       Impact factor: 5.157

9.  Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans.

Authors:  Zaiqi Wang; Stephen D Hall; Juan F Maya; Lang Li; Ali Asghar; J C Gorski
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

10.  A cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: Application to acetaminophen.

Authors:  Anaïs Michaut; Dounia Le Guillou; Caroline Moreau; Simon Bucher; Mitchell R McGill; Sophie Martinais; Thomas Gicquel; Isabelle Morel; Marie-Anne Robin; Hartmut Jaeschke; Bernard Fromenty
Journal:  Toxicol Appl Pharmacol       Date:  2015-12-29       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.